Skip to main content

Name
Daniel Rivera

Tue, 09/24/2019 - 09:30

Thank you to Dr. Carrier for his presentations on the application of DOACs to treat VTE in cancer patients. As mentioned, there seems to be a split between the clinicians polled at the grand round - certainly interesting given that fairly compelling evidence was presented. Does raise the question, what will it take to convince clinicians further? More clear direction/information around DOAC use in clinical guidelines?

Dr. Carrier also raised a great point that day - what does this all mean to patients? VTE may not be on the top of a cancer patients mind, especially when pre-occupied with chemo + other treatments/symptoms associated with their primary concern, the cancer itself. However, it has been mentioned that cancer patients are at an increased risk for VTE. I'm interested to see how both patient and clinician interest in DOAC use for VTE takes off as more literature comes out and finds its way to those who create clinical guidelines.

Name
Daniel Rivera

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.